

Patent Case No. IN0964Q

#9  
TDS  
w/attach  
1/16/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Carlos O. Stalgis,et al. : Examiner: Shanon A.Foley  
For Patent for: RIBAVIRIN-PEGYLATED :  
INTERFERON ALFA HCV :  
COMBINATION THERAPY :  
Serial No. 09/464,426 : Group Art Unit: 1648  
Filed: 12/16/1999 :  
TECH CENTER 1600/2930

RECEIVED  
JAN 15 2009

Assistant Commissioner for Patents  
Washington, D.C. 20231

## **INFORMATION DISCLOSURE STATEMENT**

Sir:


In accordance with the applicant's duty of disclosure expressed in 37 C.F.R. § 1.56, the Examiner's attention is directed to the documents listed on the accompanying form PTO-1449.

Inclusion of a document is not an admission that the document is prior art with respect to the invention of the application and is not to be construed as an admission that anything in the document renders any claim of the application unpatentable.

A copy of each listed document is enclosed for the convenience of the Examiner, which copy is the best available to the Applicant at this time; the Examiner is requested to disregard any underlining or marginal notation (if any) appearing in a copy, since marking may have been done for another purpose and not pertain in any manner to the subject application.

Consideration of the document, and the return of an initialed copy of the duplicate copy of the enclosed form PTO-1449 to indicate such consideration, are respectfully requested.

Respectfully submitted,

  
Thomas D. Hoffman  
Attorney of Record for Applicant  
Registration No. 28,221  
Tel. No. (908) 298-5037

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on

December 14, 2001  
Date of Signature

Thomas D. Hoffman  
Registered Representative

  
Thomas D. Hoffman 12/14/2001  
Signature & Date of Signature

Schering-Plough Corporation  
Patent Department, K-6-1-1990  
2000 Galloping Hill Road  
Kenilworth, New Jersey 07033-0530


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on

December 14, 2001

Date

THOMAS D.HOFFMAN

Typed or Printed Name



Signature

12/14/2001

Date of Signature

TECH CENTER 1600/2900

JAN 15 2002

RECEIVED

PATENT Docket No.:IN0964Q

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----X  
In re Application of: CARLOS O. STALGIS :

For: RIBAVIRIN-PEGYLATED INTERFERON  
ALFA INDUCTION HCV COMBINATION  
THERAPY : Examiner: SHANON A. FOLEY  
Serial No.: 09/464,426 : Group Art Unit: 1648  
Filed: 12/16/1999 :  
-----X

Assistant Commissioner for Patents  
Washington, D.C. 20231

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT PURSUANT TO**  
**37 C.F.R. 1.97(c) OR (d)**

Sir:

37 C.F.R. 1.97(c)

1.a.  The information disclosure statement transmitted herewith is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

- (1) a final action under § 1.113, or
- (2) a notice of allowance under § 1.311, whichever occurs first.

1.b.  This statement is accompanied by the certification set forth below. OR

1.c.  Applicant(s) elect to pay the fee of \$180.00 for the submission of this information disclosure statement.

37 C.F.R. 1.97(d)

- 2.a.  The information disclosure statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.
- 2.b.  This statement is accompanied by the certification set forth below. AND
- 2.c.  Applicant(s) hereby petition for the consideration of the accompanying information disclosure statement. AND
- 2.d.  The fee for this petition is \$130.00.

METHOD OF PAYMENT

- 3.a.  Charge \$\_\_\_\_\_ to Deposit Account No. 19-0365.
- 3.b.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0365.

CERTIFICATION

4.  I, the person signing below, hereby certify
  - that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
  - that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or to the knowledge of the person signing the certification, after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of the statement.

---

Name of Person Making Certification

---

Signature

---

Date

Respectfully submitted,



THOMAS D. HOFFMAN

Patent Department, K-6-1, 1990  
SCHERING-PLOUGH CORPORATION  
2000 Galloping Hill Road  
Kenilworth, New Jersey 07033-0530

Attorney/Agent for Applicant(s)  
Registration No.: 28221  
Telephone No.: (908) 298-5037  
Facsimile No. (908) 298-5388